There's plenty of papers dedicated to understanding this known and identified risk. FDA will very aware of them and certainly competitors will be very, very aware of them when/if iPSCs ever go before an ODAC panel for their first approval. Look at the effort Novartis et. al. went to in preparing a 'citizen's' letter against Mesoblast's for its ODAC review for an unmet need in dying infants. There are no bounds in the depths of low of Big Pharma's depraved dark pits of greed.
Here's just one recent paper. Many questions still to answer and a decade or two of research away from just answering these questions, imo.
https://academic.oup.com/pcm/article/5/1/pbac004/6521459
There's plenty of papers dedicated to understanding this known...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |